Lilly Acquires AtaiBeckley to Advance Depression Therapies
INDIANAPOLIS and NEW YORK, July 16, 2026 Eli Lilly and Company has announced a definitive agreement to acquire AtaiBeckley...
Eli Lilly
Advertisement
Chai Discovery Secures $400M to Transform AI Drug Discovery
SAN FRANCISCO, July 17, 2026 Chai Discovery has announced the successful completion of a $400 million Series C financing...
AbbVie Reports Positive Phase 3 Epcoritamab DLBCL Results
NORTH CHICAGO, Ill., June 29, 2026 AbbVie has announced positive topline results from the Phase 3 EPCORE® DLBCL-4 clinical...
FDA Selects Seven Firms for PreCheck Manufacturing Pilot
SILVER SPRING, Md., June 29, 2026 The U.S. Food and Drug Administration (FDA) has announced the selection of seven...
Lilly Jaypirca CHMP Backs EU Approval for CLL Treatment
INDIANAPOLIS, June 26, 2026 Eli Lilly and Company announced that the European Medicines Agency’s Committee for Medicinal Products for...
Advertisements
Abbisko Therapeutics and Lilly Expand Global R&D Partnership
SHANGHAI, June 23, 2026 Abbisko Therapeutics Co., Ltd. announced a strategic research collaboration and license agreement with Eli Lilly...
5W AI Index Reveals New Pharma Visibility Leaders Online
BOCA RATON, Fla., June 19, 2026 5W AI Communications has released its Pharma / Rx AI Visibility Index 2026,...
Lilly’s Jaypirca Reduces Risk of Disease Progression or Death by 45% in CLL/SLL
INDIANAPOLIS, Indiana, June 14, 2026 Eli Lilly and Company announced compelling results from the pivotal Phase 3 BRUIN CLL-322...
Novartis and Orionis Expand AI-Powered Molecular Glue Alliance
BOSTON, Massachusetts, USA and GHENT, Belgium, June 10, 2026 Orionis Biosciences and Novartis have announced a major multi-year strategic...
Teva Acquires Emalex to Advance Tourette Syndrome Therapy
TEL AVIV, Israel, June 10, 2026 Teva Pharmaceutical Industries Ltd. has completed its acquisition of Emalex Biosciences, strengthening its...
Advertisement
